The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

post
Complete Guide to NDA vs. ANDA: Differences, Processes, and Requirements
Read More

post
Regulatory Medical Writing: What Is It and What Do They Do?
Read More

post
CMC Safety and Efficacy in Gene and Cell Therapies
Read More

post
Accelerating Drug Development: Regulatory Strategies for Fast-Track and Breakthrough Therapy Designations
Read More
Let's move from science to success.
Let’s Talk